Abstract
The aim of this study is to evaluate the frequency and results of retests in patients whose cervical cytology was reported as 'Negative for intraepithelial lesion or malignancy', but for whom retest was recommended due to borderline adequacy, borderline evaluability or mild atypia attributable to benign causes. All cervical cytology reports evaluated in the pathology laboratory of Şanlıurfa Training and Research Hospital between 01.06.2022-01.06.2023 were examined. Four thousand three hundred eighty-five of the 5025 cervical cytologies were reported as negative. Retests were recommended for 820. Inflammation was detected in 96.22% of cases, parabasal cell predominance in 11.58%, hypocellularity in 6.58%, fibrin in 5.73%, bacterial vaginosis in 2.80%, Candida in 2.56%. Human papillomavirus (HPV) negativity was detected in 38.30% of patients, HPV positivity in 1.80%. Previous normal cervical cytology was present in 17.20% of patients, previous abnormal cervical cytology in 2.20%, previous normal cervical biopsy in 0.90%, previous abnormal cervical biopsy in 2.00%. Only 7.20% of patients underwent repeat testing within the following one year, and abnormalities were reported in only 6.78% of these retests. The retest rate was significantly higher in patients with previous normal cervical cytology and previous abnormal cervical biopsy. No significant relationship was found between the frequency of repeat testing and age, residence, the clinic where the patients were examined, presence and results of HPV test, presence and results of follow up biopsy. Both the frequency of repeat testing and the frequency of abnormality detected in the retest are low. However, since it is a minimal invasive procedure, we believe that repeat cytology when recommended, is an appropriate approach to identify this small number of abnormal patients.

This publication has 19 references indexed in Scilit: